Trial Exploring the Efficacy and Safety of FE 202767



Status:Not yet recruiting
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:18 - 44
Updated:5/11/2016
Start Date:March 2017
End Date:June 2018
Contact:Clinical Development Support
Email:DK0-Disclosure@ferring.com

Use our guide to learn which trials are right for you!

A Randomised, Double-blind, Placebo-controlled, Multicentre Trial Exploring the Efficacy and Safety of Intra-nasal Administration of FE 202767 in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production

This trial investigates the safety and efficacy of FE 202767 compared to placebo in
increasing milk production in subjects with preterm delivery and inadequate milk production.


Inclusion Criteria:

- Provided informed consent for the maternal subject and parental consent for the
infant(s), prior to any trial activity

- Is a maternal subject aged 18 to 44 years

- Delivered at the hospital associated with the trial centre

- Had at least 1 and no more than 2 live-born infants from the current delivery

- Delivered preterm at gestational week 24/0 to 31/6

- Attempted initial milk expression within 12 hours of delivery

- Is willing to express milk 6 to 8 times daily, including at least once during the
night and with no more than 5 hours between milk expression sessions, for up to 23
days during observation, treatment, and follow-up periods

- After the first 24 hours following delivery, attempted milk expression at least 3
times every 24 hours at each consecutive 24-hour interval

- Is willing to refrain from sexual intercourse during the trial

- Has been instructed to express milk 6 to 8 times daily, including at least once
during the night and with no more than 5 hours between milk expression sessions

- Attempted milk expression using the breast pump at least 5 times every 24 hours
during the observation period; note that subjects who entered the observation period
soon after delivery will not be excluded if they pumped less frequently in the first
48 hours after delivery, as long as they have met inclusion criteria 6 and 8

- Accurately recorded timing of milk expression after providing informed consent

- Produced <200 mL milk at the 24-hour baseline interval towards the end of the
observation period, i.e. within 24 hours prior to the last milk expression session
using the breast pump before randomisation

- Delivered 96 to 144 hours prior to randomisation

Exclusion Criteria:

- Has morbidity (chronic or temporary) or other condition or situation that would cause
her to be unable to comply with the protocol or be unable to attend all trial visits

- Has mastitis

- Had known breast trauma, previous breast surgery (including breast augmentation or
breast reduction) or nipple piercing

- Has known prolactin-releasing pituitary tumour, a history of Sheehan's syndrome, or
had previous pituitary surgery or radiation therapy

- Has any known maternally driven contraindication to breast-feeding

- Has severe cardiovascular disease (e.g., uncontrolled hypertension, severe
arrhythmias, or Grade 3-4 New York Heart Association cardiac failure)

- Has pre-pregnancy insulin-dependent diabetes mellitus, polycystic ovarian syndrome,
or any other condition that would impact lactation in the opinion of the investigator

- Has unstable thyroid disease, i.e., has required dose adjustment of thyroid
replacement or anti-thyroid medication in the 12 months prior to delivery

- Has known moderate or severe renal or hepatic impairment

- Has used or is currently using any of the following concomitant medications:

- Atypical anti-psychotic drugs during the previous 12 months (e.g., aripiprazole
[Abilify®], asenapine maleate [Saphris®], clozapine [Clozaril®], iloperidone
[Fanapt®], lurasidone [Latuda®], olanzapine [Zyprexa®], olanzapine/fluoxetine
[Symbyax®], paliperidone [Invega®], quetiapine [Seroquel®], and risperidone
[Risperdal®])

- Any non-registered investigational drugs from 90 days prior to delivery or
within 5 half-lives of the drugs, whichever is longer

- Any hormonal contraception at any point following delivery

- Any pharmacologic or complementary (e.g., herbal) galactagogue therapy at any
point following delivery, including but not limited to oxytocin, prolactin,
metoclopramide, domperidone, sulpiride, fenugreek, shatavari, torbangun, milk
thistle

- Any concomitant medication that could impact lactation (e.g., medications with
an anti-dopamine effect, such as phenothiazine and haloperidol; other
neuroleptics, such as sulpiride and risperidone; the high blood pressure
medication α-methyldopa; and medications used to stimulate intestinal
peristalsis, domperidone, and metoclopramide) at any point following delivery

- Current use of oral steroids at any dose or inhaled steroids at doses >600
µg/day

- Had postpartum haemorrhage of >1500 mL

- Has used or is currently using any of the following concomitant medications:

- Prostaglandins at any point after providing informed consent

- Any current intra-nasally administered concomitant medications

- Methergine from 12 hours prior to randomisation
We found this trial at
14
sites
Loma Linda University
Loma Linda, California 92354
(909) 558-4000
Loma Linda University Loma Linda University (LLU) is a Seventh-day Adventist educational health-sciences institution with...
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
655 West Baltimore Street
Baltimore, Maryland 21201
(410) 706-7410
University of Maryland School of Medicine Established in 1807, The School of Medicine is the...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Murray, Utah 84107
?
mi
from
Murray, UT
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Raleigh, North Carolina 27610
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
615 N Michigan St
South Bend, Indiana 46601
(574) 647-1000
Memorial Hospital of South Bend Memorial Hospital of South Bend is a community-owned, not-for-profit corporation...
?
mi
from
South Bend, IN
Click here to add this to my saved trials
Winston Salem, North Carolina 27103
?
mi
from
Winston Salem, NC
Click here to add this to my saved trials